Literature DB >> 29159748

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.

Oluwadamilola M Fayanju1,2, Ko Un Park3, Anthony Lucci4,5.   

Abstract

Molecular genomic testing provides clinicians with both prognostic and (sometimes) predictive information that can help individualize treatment and decrease the risk of over- or under-treatment. We review the genomic tests that are currently available for clinical use in management of breast cancer, discuss ongoing research related to validating and expanding their utility in different patient populations, and explain why it is important for surgeons to know how to incorporate these tools into their clinical practice in order to individualize patient treatment, reduce unnecessary morbidity, and, accordingly, improve outcomes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29159748      PMCID: PMC5790421          DOI: 10.1245/s10434-017-6254-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  35 in total

1.  Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.

Authors:  Melody A Cobleigh; Bita Tabesh; Pincas Bitterman; Joffre Baker; Maureen Cronin; Mei-Lan Liu; Russell Borchik; Juan-Miguel Mosquera; Michael G Walker; Steven Shak
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

2.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

3.  The MINDACT trial: the first prospective clinical validation of a genomic tool.

Authors:  Fatima Cardoso; Martine Piccart-Gebhart; Laura Van't Veer; Emiel Rutgers
Journal:  Mol Oncol       Date:  2007-10-22       Impact factor: 6.603

4.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Edith A Perez; John A Olson; JoAnne Zujewski; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; James N Atkins; Jeffrey L Berenberg; George W Sledge
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

5.  A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.

Authors:  Denise A Yardley; Nancy W Peacock; Mythili Shastry; Howard A Burris; Rebecca G Bechhold; Carolyn B Hendricks; Carl N Yoshizawa; Amy P Sing; John D Hainsworth
Journal:  Breast Cancer Res Treat       Date:  2015-10-27       Impact factor: 4.872

6.  Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

Authors:  Jack Cuzick; Mitch Dowsett; Silvia Pineda; Christopher Wale; Janine Salter; Emma Quinn; Lila Zabaglo; Elizabeth Mallon; Andrew R Green; Ian O Ellis; Anthony Howell; Aman U Buzdar; John F Forbes
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

7.  Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer.

Authors:  E A Rakha; D Soria; A R Green; C Lemetre; D G Powe; C C Nolan; J M Garibaldi; G Ball; I O Ellis
Journal:  Br J Cancer       Date:  2014-03-11       Impact factor: 7.640

Review 8.  Multigene prognostic tests in breast cancer: past, present, future.

Authors:  Balázs Győrffy; Christos Hatzis; Tara Sanft; Erin Hofstatter; Bilge Aktas; Lajos Pusztai
Journal:  Breast Cancer Res       Date:  2015-01-27       Impact factor: 6.466

Review 9.  Individualization of therapy using Mammaprint: from development to the MINDACT Trial.

Authors:  Stella Mook; Laura J Van't Veer; Emiel J T Rutgers; Martine J Piccart-Gebhart; Fatima Cardoso
Journal:  Cancer Genomics Proteomics       Date:  2007 May-Jun       Impact factor: 4.069

10.  A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.

Authors:  Lawrence J Solin; Robert Gray; Frederick L Baehner; Steven M Butler; Lorie L Hughes; Carl Yoshizawa; Diana B Cherbavaz; Steven Shak; David L Page; George W Sledge; Nancy E Davidson; James N Ingle; Edith A Perez; William C Wood; Joseph A Sparano; Sunil Badve
Journal:  J Natl Cancer Inst       Date:  2013-05-02       Impact factor: 13.506

View more
  7 in total

1.  The Role of Oncotype DX® Recurrence Score in Predicting Axillary Response After Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Jaime A Pardo; Betty Fan; Alessandra Mele; Stephanie Serres; Monica G Valero; Isha Emhoff; Amulya Alapati; Ted A James
Journal:  Ann Surg Oncol       Date:  2021-01-03       Impact factor: 5.344

Review 2.  Breast cancer in the era of precision medicine.

Authors:  Negar Sarhangi; Shahrzad Hajjari; Seyede Fatemeh Heydari; Maryam Ganjizadeh; Fatemeh Rouhollah; Mandana Hasanzad
Journal:  Mol Biol Rep       Date:  2022-06-22       Impact factor: 2.742

Review 3.  Genomic Assays in Node Positive Breast Cancer Patients: A Review.

Authors:  Maroun Bou Zerdan; Maryam Ibrahim; Clara El Nakib; Rayan Hajjar; Hazem I Assi
Journal:  Front Oncol       Date:  2021-02-16       Impact factor: 6.244

Review 4.  Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?

Authors:  Liqin Yao; Gang Jia; Lingeng Lu; Wenxue Ma
Journal:  Curr Oncol       Date:  2022-07-12       Impact factor: 3.109

5.  Hospital Rurality and Gene Expression Profiling for Early-Stage Breast Cancer among Iowa Residents (2010-2018).

Authors:  Danielle Riley; Mary Charlton; Elizabeth A Chrischilles; Ingrid M Lizarraga; Sneha Phadke; Brian J Smith; Adam Skibbe; Charles F Lynch
Journal:  Breast J       Date:  2022-08-30       Impact factor: 2.269

6.  A tumor microenvironment-related risk model for predicting the prognosis and tumor immunity of breast cancer patients.

Authors:  Shengkai Geng; Yipeng Fu; Shaomei Fu; Kejin Wu
Journal:  Front Immunol       Date:  2022-08-18       Impact factor: 8.786

Review 7.  Panoptic View of Prognostic Models for Personalized Breast Cancer Management.

Authors:  Geetanjali Saini; Karuna Mittal; Padmashree Rida; Emiel A M Janssen; Keerthi Gogineni; Ritu Aneja
Journal:  Cancers (Basel)       Date:  2019-09-07       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.